Scholarlink

<p>This study evaluates the prevalence and implications of Non-thyroidal Illness Syndrome (NTIS) in children with acute lymphoblastic leukemia (ALL), marking a focus shift towards pediatric patients who have been less studied in this context. Through a prospective analysis of 96 newly diagnosed ALL patients against healthy controls, we assessed thyroid function at diagnosis and after induction chemotherapy. Our findings highlight a significant reduction in T3/FT3 and FT4 levels in the ALL group, with NTIS prevalence jumping from 44.8% pre-chemotherapy to 74.2% post-chemotherapy, illustrating the profound impact of treatment-related factors and inflammation on thyroid health. Unlike previous beliefs, NTIS’s occurrence was independent of ALL risk categories and induction therapy outcomes. Factors like elevated C-reactive protein, low serum albumin, and lymphoblast count emerged as NTIS risk indicators. Most thyroid dysfunctions normalized post-chemotherapy without needing hormonal interventions, suggesting a transient NTIS that favors conservative management focused on long-term monitoring. This study not only confirms the high incidence of NTIS in pediatric ALL patients but also challenges existing thyroid health management paradigms in pediatric oncology, calling for nuanced treatment approaches.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Changes in thyroid hormone status following induction chemotherapy in patients with pediatric acute lymphoblastic leukemia

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月8日

查看全文
  • Jingzi Zhong,
  • Haini Yang,
  • Dan Zeng,
  • Dan Lan

摘要

This study evaluates the prevalence and implications of Non-thyroidal Illness Syndrome (NTIS) in children with acute lymphoblastic leukemia (ALL), marking a focus shift towards pediatric patients who have been less studied in this context. Through a prospective analysis of 96 newly diagnosed ALL patients against healthy controls, we assessed thyroid function at diagnosis and after induction chemotherapy. Our findings highlight a significant reduction in T3/FT3 and FT4 levels in the ALL group, with NTIS prevalence jumping from 44.8% pre-chemotherapy to 74.2% post-chemotherapy, illustrating the profound impact of treatment-related factors and inflammation on thyroid health. Unlike previous beliefs, NTIS’s occurrence was independent of ALL risk categories and induction therapy outcomes. Factors like elevated C-reactive protein, low serum albumin, and lymphoblast count emerged as NTIS risk indicators. Most thyroid dysfunctions normalized post-chemotherapy without needing hormonal interventions, suggesting a transient NTIS that favors conservative management focused on long-term monitoring. This study not only confirms the high incidence of NTIS in pediatric ALL patients but also challenges existing thyroid health management paradigms in pediatric oncology, calling for nuanced treatment approaches.